BNR
- Burning Rock Biotech Limited
()
Overview
Company Summary
Burning Rock Biotech Limited (BNR) is a leading company in the field of molecular diagnostics and cancer genomics. The company specializes in developing and commercializing next-generation sequencing (NGS) based genetic testing products for oncology.
Burning Rock Biotech utilizes advanced technologies, such as NGS, to analyze and interpret genetic information from patient samples. By studying the genetic mutations and variations in cancer cells, they aim to provide accurate and comprehensive molecular profiling to aid in cancer diagnosis, treatment selection, and monitoring of disease progression.
The company's product portfolio includes a wide range of diagnostic assays, including tissue-based panels, blood-based liquid biopsy tests, and companion diagnostics. These tests play a crucial role in personalized medicine, enabling doctors to make informed decisions about treatment options based on the unique genomic characteristics of each patient's tumor.
Burning Rock Biotech's molecular diagnostic solutions cover various cancer types, such as lung, colorectal, gastric, and breast cancers. They also offer specialized tests for rare and difficult-to-diagnose cancers, facilitating early detection and tailored treatment plans.
In addition to their diagnostic services, Burning Rock Biotech actively collaborates with pharmaceutical companies, clinical research organizations, and academic institutions. They provide support for research and development of novel therapeutics, clinical trial sample testing, and companion diagnostic development to accelerate the advancement of precision medicine.
With a focus on innovation and quality, Burning Rock Biotech aims to revolutionize cancer diagnosis and treatment through the integration of cutting-edge technologies and comprehensive genomic analysis. Their mission is to improve patient outcomes by providing oncologists and researchers with actionable insights into the underlying biology of cancer.